EXHIBIT 99.1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date: January 22, 2025

 

POINT72 ASSET MANAGEMENT, L.P.  
   
   
/s/ Jason M. Colombo  
Name: Jason M. Colombo  
Title: Authorized Person  
   
POINT72 CAPITAL ADVISORS, INC.  
   
   
/s/ Jason M. Colombo  
Name: Jason M. Colombo  
Title: Authorized Person  
   
   
STEVEN A. COHEN  
   
   
/s/ Jason M. Colombo  
Name: Jason M. Colombo  
Title: Authorized Person  

 

 

 

Syndax Pharmaceuticals (NASDAQ:SNDX)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Syndax Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Syndax Pharmaceuticals (NASDAQ:SNDX)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Syndax Pharmaceuticals 차트를 더 보려면 여기를 클릭.